{"id":"high-dose-rosuvastatin-single-administration","safety":{"commonSideEffects":[{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Rhabdomyolysis (rare)"}]},"_chembl":{"chemblId":"CHEMBL1744447","moleculeType":"Small molecule","molecularWeight":"1001.15"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rosuvastatin is a statin that competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. This leads to decreased intracellular cholesterol production, upregulation of LDL receptors on hepatocytes, and enhanced clearance of LDL cholesterol from the bloodstream. High-dose single administration is used to rapidly achieve therapeutic cholesterol-lowering effects.","oneSentence":"Rosuvastatin inhibits HMG-CoA reductase to reduce cholesterol synthesis and lower LDL cholesterol levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:24:22.138Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia and dyslipidemia"},{"name":"Primary and secondary prevention of cardiovascular disease"}]},"trialDetails":[{"nctId":"NCT07012629","phase":"PHASE3","title":"A EUROpean Randomized Study on Blood-thinners and Cholesterol-lowering Treatments to Prevent Future Vascular Events in People With Covert Brain Infarcts (CBI)","status":"RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2025-11-26","conditions":"Covert Brain Infarction","enrollment":1652},{"nctId":"NCT04499859","phase":"PHASE4","title":"Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI","status":"RECRUITING","sponsor":"Kiyuk Chang, MD,PhD","startDate":"2020-10-01","conditions":"Myocardial Infarction, Statin Adverse Reaction, HMG-CoA Reductase Inhibitor Toxicity","enrollment":3548},{"nctId":"NCT07001787","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HS-10510 in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2025-06","conditions":"Dyslipidemia","enrollment":88},{"nctId":"NCT05787002","phase":"PHASE1","title":"A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-03-09","conditions":"Dyslipidemia","enrollment":16},{"nctId":"NCT06533280","phase":"PHASE1","title":"VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)","status":"WITHDRAWN","sponsor":"ViiV Healthcare","startDate":"2024-08-02","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT05384262","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-05-18","conditions":"Dyslipidemia","enrollment":183},{"nctId":"NCT01563731","phase":"PHASE4","title":"Optimal Blood Pressure and Cholesterol Targets for Preventing Recurrent Stroke in Hypertensives","status":"COMPLETED","sponsor":"Istituto Auxologico Italiano","startDate":"2013-04","conditions":"Stroke, Transient Ischemic Attack, Hypertension","enrollment":200},{"nctId":"NCT06262685","phase":"PHASE4","title":"Efficacy, Safety and Cost-efficacy of a Pre-emptive Genotyping Strategy in Patients Receiving Statins","status":"UNKNOWN","sponsor":"Instituto de Investigación Hospital Universitario La Paz","startDate":"2024-03-04","conditions":"Cardiovascular Diseases, Dyslipidemias, Statin Adverse Reaction","enrollment":216},{"nctId":"NCT05395117","phase":"PHASE1","title":"A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and Digoxin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-06-30","conditions":"Healthy Participants","enrollment":32},{"nctId":"NCT05884502","phase":"PHASE4","title":"A Multicenter Study to Evaluate the Effect of High Dose Rosuvastatin Versus Rosuvastatin and Ezetimibe in Stroke","status":"UNKNOWN","sponsor":"Korea University Anam Hospital","startDate":"2022-09-01","conditions":"Dyslipidemias, Stroke, Acute Ischemic","enrollment":330},{"nctId":"NCT02476006","phase":"PHASE3","title":"Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-06-23","conditions":"Hypercholesterolemia","enrollment":998},{"nctId":"NCT03355027","phase":"NA","title":"Investigating the Lowest Threshold of Vascular Benefits From LDL Cholesterol Lowering in Patients With Stable CV Disease","status":"UNKNOWN","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2017-11-30","conditions":"Atherosclerosis, Cardiovascular Diseases","enrollment":60},{"nctId":"NCT01342211","phase":"PHASE2","title":"A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-07","conditions":"Hypercholesterolemia, Dyslipidemia","enrollment":93},{"nctId":"NCT02305862","phase":"NA","title":"A High-Resolution Magnetic Resonance Imaging Study to Evaluate the Effect of Rosuvastatin on Carotid Atherosclerotic Plaques","status":"UNKNOWN","sponsor":"Capital Medical University","startDate":"2013-01","conditions":"Arteriosclerosis, Diabetes Mellitus, Lipid Disorder","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"high-dose rosuvastatin single administration","genericName":"high-dose rosuvastatin single administration","companyName":"Korea University Anam Hospital","companyId":"korea-university-anam-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rosuvastatin inhibits HMG-CoA reductase to reduce cholesterol synthesis and lower LDL cholesterol levels. Used for Hypercholesterolemia and dyslipidemia, Primary and secondary prevention of cardiovascular disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}